SciELO - Scientific Electronic Library Online

 
vol.27 número2Método rápido de verificación de mutantes de Escherichia coli empleados en ingeniería genética índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

  • No hay articulos citadosCitado por SciELO

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Vaccimonitor

versión impresa ISSN 1025-028Xversión On-line ISSN 1025-0298

Resumen

GONZALEZ-VILLANUEVA, Layda et al. Preliminary evaluation and updating of the productive losses to improve the profitability of Finlay. Vaccimonitor [online]. 2018, vol.27, n.2, pp.37-44. ISSN 1025-028X.

A preliminary evaluation of production losses was carried out in several scenarios of the Aseptic Processing and Packaging Plant of Finlay Vaccine Institute, Havana, Cuba. The evaluation covered the areas of formulation, filling, labeling and packaging, during the period 2011-2015, with the purpose of constituting a useful tool that would influence the production costs and improve the efficiency of the company. The results show that the formulation stage presents a higher average loss due to wastage (6.99%), mainly contributed by the vaccines DTP-vax® and VA-MENGOC-BC®; followed by the filling stage with an average loss of 4%. The losses for the rest of the stages ranged between 0.2% and 1.57%. The general cost of the losses of this period was 8,949,871.79 Cuban pesos, contributed by vax-SPIRAL®, vax-TyVi®, vax-TET® and VA-MENGOC-BC® vaccines. It was observed that, except for vax-TET-5)® (presentation of 20 doses), due to problems faced with the volume of the bulbs, the losses of the year 2016 were below the established percentage. Finally, a trend analysis was made of the total losses and by presentation, in the period 2011 to 2016, showing that in 2015 the highest quantity of vaccine losses was obtained, with a higher incidence in the presentation of 20 doses

Palabras clave : productive losses; vaccines; production costs; trend analysis.

        · resumen en Español     · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons